A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)

Giovanni Cappello,Valentina Giannini,Roberto Cannella,Emanuele Tabone,Ilaria Ambrosini, Francesca Molea,Nicolò Damiani, Ilenia Landolfi,Giovanni Serra,Giorgia Porrello,Cecilia Gozzo,Lorena Incorvaia,Giuseppe Badalamenti,Giovanni Grignani,Alessandra Merlini,Lorenzo D’Ambrosio,Tommaso Vincenzo Bartolotta,Daniele Regge

European Journal of Radiology Open（2023）

Cited 0|Views18

No score

Abstract

•Only GIST with specific genotypes are sensitive to imatinib.•Radiomics helps to correlate pre-treatment CT features to GIST mutational status, predicting response to imatinib treatment.•The developed radiomics signature improve treatment allocation, accuracy and appropriateness.

Translated text

Key words

Artificial intelligence, Radiomics, GIST, Mutational status, Response to therapy

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined